DNA X, Inc. 8-K

What Happened

• DNA X, Inc. (SONM) filed an 8-K on July 2, 2026 announcing a securities purchase agreement dated June 29, 2026 with DNA Holdings Venture, Inc., a holder of >5% of the company and an entity associated with board member Scott Walker.
• Under the agreement the company agreed to issue 1,346,531 shares of non‑voting Series B Convertible Preferred Stock at $6.00 per share (stated value), for an aggregate offering price of $8.1 million, consisting of $5.0 million in cash proceeds plus cancellation of $3.1 million of an outstanding convertible promissory note issued to DNA Holdings in May 2026.
• The Series B Preferred will automatically convert into Common Stock only after the company’s stockholders approve the issuance of the Common Stock issuable on conversion; until that stockholder approval the Series B is not convertible.

Key Details

• Transaction date: Purchase Agreement executed June 29, 2026; 8-K filed July 2, 2026.
• Shares/price: 1,346,531 Series B Preferred at $6.00 per share; aggregate $8.1M (approx. $5.0M cash proceeds).
• Note treatment: $3.1M of an outstanding convertible note to DNA Holdings will be cancelled as part of the consideration.
• Related-party and follow-on rights: DNA Holdings is a >5% holder and is associated with a director; agreement grants DNA Holdings a 12‑month participation right in future financings (cap = 50% of securities sold).
• Registration rights: Company agreed to file a resale registration statement within 30 days after stockholder approval (Form S‑3 or S‑1) and to use commercially reasonable efforts to keep it effective; liquidated damages apply for certain failures.
• Consulting/Promote agreement: At closing the company expects to enter an advisory agreement with DNA Holdings, Scott Walker and Brock Pierce to receive a total of 2,494,000 shares of Common Stock upon stockholder approval.

Why It Matters

• Financing and liquidity: The deal provides roughly $5.0M of immediate cash to fund working capital and corporate needs, while converting $3.1M of debt into preferred equity, improving near‑term liquidity and balance sheet flexibility.
• Potential dilution and resale: The Series B will convert into Common Stock if stockholders approve the issuances, which would dilute existing common shareholders; registration rights mean converted shares could be registered for resale, increasing potential supply of tradable common shares.
• Related‑party governance: The counterparty is a significant existing holder associated with a board member, making this a related‑party transaction — investors should note potential governance and conflict considerations and that several items (conversion and consultant share issuances) require stockholder approval.
• Future impact: DNA Holdings’ participation rights and the planned consultant share issuance (2,494,000 shares) could lead to additional dilution if approved; deadlines and registration obligations create milestones that could affect timing of resale and stock float.